A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence - a ...
For clinicians, bladder stones (vesical calculi) are less a disease and more a symptom of a deeper problem, usually stasis or ...
Understand the key factors influencing breast cancer recurrence and discover effective treatments and lifestyle changes that ...
To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,ā said study presenter Stephen J. Freedland, MD.
The odds of cancer returning, known as risk of recurrence, depends on several factors, including tumor type, stage, and size; ...
McGill University scientists have uncovered how loss of the protein ERRĪ³ drives lethal neuroendocrine prostate cancer and ...
aDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan bDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, ...
A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of ...
Statistics for pancreatic cancer haven't changed much for decades despite progress that has cut the death toll for some other kinds of cancer.
In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback